Drugs / SARS-CoV-2 Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04866069 | Apr → Sep 2021 | COVID-19 | Osman ERGANIS, PhD, Prof | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06694389 Comparator | Nov 2024 → Nov 2025 | COVID-19, influenza | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06694389 ↗ |
| Modality | Vaccine | “Adjuvanted inactivated vaccine” NCT04866069 ↗ |
| Route | Subcutaneous | “All injections will be done subcutaneously.” NCT04866069 ↗ |